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Novel paediatric presentation of COVID-19 with ARDS and 
cytokine storm syndrome without respiratory symptoms
Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) is the pathogen that causes COVID-19. Although 
early studies suggested that children and adolescents 
could be spared from severe disease, reports have since 
been published of children hospitalised or dying from 
COVID-19.1,2 We report a 14-year-old previously healthy 
individual who presented to our institution with a 3-day 
history of pyrexia, abdominal pain, nausea, and vomiting, 
but with out respiratory symptoms. The patient’s mother 
reported mild respiratory symptoms 3 weeks previously 
but the patient had not been tested for SARS-CoV-2.
On admission (day –2), the patient was febrile (38·1°C) 
and cardiovascularly stable, and showed no signs of 
respiratory distress (figure). The abdomen was tense, with 
guarding in the right upper and lower quadrants. Initial 
investigations showed lymphopenia (0·14 × 109 cells per L 
[normal range 1·5–7·6]), a signi ficant increase in C-reactive 
protein (242 mg/L [normal range 0–8]), and sterile 
pyuria (30 cells). The patient was started on empiric 
piperacillin–tazobactam for sus pected acute appendicitis, 
and nasopharyngeal swabs were sent for SARS-CoV-2 
PCR testing. Chest radiography (figure, A) and abdom-
inal ultrasound were normal. Within 24 h of admission, 
the patient developed increasing dyspnoea, cough, 
and oxygen requirement (8 L/min), finally escalating 
to continuous positive airway pressure ventilation sup-
port. The patient seemed visually more unwell and 
inter acted less, developed a widespread maculopapular 
blanch ing rash (figure, B), and received fluid boluses for 
persistent tachycardia. Chest CT showed typical findings 
of SARS-CoV-2 pneumonia (figure, C).3 A diagnosis of 
presumptive COVID-19 was made. Secondary multi-
system inflammatory disease or cytokine storm syndrome 
was diagnosed based on clinical symptoms, lympho-
penia, anaemia, thrombocyto penia, increased acute-
phase pro teins (ie, C-reactive protein and ferritin), raised 
serum interleukin (IL)-6 (1098 pg/mL [normal range 
<7]), coagulopathy (D-dimer >4810 ng/mL [normal 
range <500], pro thrombin time 16·2 s [normal range 
9·8–11·4], and activated partial thromboplastin time 
43·4 s [normal range 24·2–30·2]), increased liver enzymes 
(aspartate aminotransferase 166 IU/L [normal range 
<37] and alanine aminotransferase 156 IU/L [normal 
range <40]), and hyper triglyceridaemia (2·3 mmol/L 
[normal range 0·4–1·4]). Antinuclear antibodies tested 
negative. Anti phospholipid antibodies (anti cardiolipin 
IgG 25·5 U/mL [normal range <20] and antiβ2-
glycoprotein IgG 28·8 U/mL [normal range <20]) were 
positive, and serum complement levels were pathologically 
low (C3 0·09 g/L [normal range 0·90–1·88], C4 0·12 g/L 
[normal range 0·18–0·42]). Furthermore, the patient 
developed mild polyarticular arthritis of the small joints 
of the hands. No sub stan tial cervical lymphadenopathy, 
conjunctivitis, or mucous mem brane changes were seen to 
suggest classic or com plete Kawasaki disease.
The patient was not eligible for remdesivir com-
passionate use because SARS-CoV-2 PCR was negative. 
Because the patient showed clinical features sugges tive 
of COVID-19-associated cytokine storm syn drome,1,4 anti-
inflammatory treatment with recombinant IL-1 rec e ptor 
antagonist (anakinra) was initiated after multi disciplinary 
discussions. Anakinra was started at 4 mg/kg per day 
(100 mg twice a day) subcutaneously and increased to 
8 mg/kg per day (200 mg twice a day) after 36 h, because 
the patient required inotropic support for hypotension 
and rising lactate (6 mmol/L). Borderline left-ventricular 
systolic dysfunction, enzyme leak (troponin-T 45 ng/L), 
aortic regurgitation, and pro gressive left coronary dila-
tation were noted (figure, D), and aspirin was started 
(2 mg/kg) for its anti thrombotic effects. Of note, Kawasaki 
disease-like features, including coronary aneurysms, have 
been rep orted in patients with COVID-19.2 Since coronary 
artery dilation can occur in the context of systemic 
inflammatory disease, endothelial activation, or both,5 
and because the patient did not show additional clinical 
features of Kawasaki disease, we did not start intravenous 
immuno globulin or corticosteroids, after weighing the 
risks associated with intravenous immunoglobulin treat-
ment (ie, thromboembolic events, aseptic meningitis, 
and antibody-dependent enhancement).
In temporal relation with anakinra treatment, the 
patient’s respiratory status stabilised and clinical and 
laboratory variables returned to normal (figure, E), with the 
exception of coronary dilation that persisted at the time of 
discharge. Thus, anakinra was tapered and discontinued 
after 6 days. Subsequently, serum tested positive for 
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SARS-CoV-2 IgG (borderline day 6, positive day 11). SARS-
CoV-2 PCR on three nasopharyngeal samples (days 3, 5, 
and 7) and stool (day 11) were negative. 
To our knowledge, this case is the first paediatric 
patient reported with cytokine storm syndrome during 
the COVID-19 pandemic presenting without respiratory 
symptoms on hospital admission who was successfully 
treated with IL-1 inhibition. Although respiratory and 
stool PCR testing was negative, CT chest findings and 
biochemical and haematological variables were highly 
suggestive of COVID-19, with evidence of seroconversion. 
Considering that PCR test sensitivity ranges around 
60%, after three negative PCR results, this case could 
represent a post-COVID-19 inflammatory process. An 
alternative explanation could be viral replication at an 
alternative site. Although the patient developed early-
stage acute respiratory distress syndrome (ARDS) in 
the hospital (severe oxygenation defect and bilateral 
pulmonary infiltrates), respiratory symptoms were not 
part of the initial presentation. Thus, the case resembles a 
previously unappreciated clinical phenotype of COVID-19 
in children with rapid onset ARDS and cytokine storm 
syndrome after fever and abdominal pain in the absence 
of preceding respiratory symptoms.1,2
Based on our current pathophysiological under stand-
ing, SARS-CoV-2 replicates in respiratory and intes tinal 
epithelial cells and suppresses early type I inter feron res-
ponses. Furthermore, SARS-CoV-2 can abort ively infect 
innate immune cells (monocytes and macro phages), 
which can be facilitated by immune com plexes, acceler-
ating viral replication and amplify ing pro inflam matory 
cytokine (IL-1, IL-6, tumour nec rosis factor [TNF]) release 
in a process termed antibody-dependent enhancement. 
Viral replication results in tissue damage and excessive 
recruitment of innate and adaptive immune cells, which 
mediates a dysregulated hyperinflammatory response 
Figure: Clinical findings in a 14-year-old patient with COVID-19 and cytokine 
storm syndrome
Although chest radiography was normal at admission (day –2; A, left panel), 
follow-up imaging 4 days later (A, right panel) showed dense infiltrates 
suggestive of early-stage acute respiratory distress syndrome in the context of 
COVID-19. A widespread maculopapular blanching rash (B) appeared on the 
second day after admission (day 0) and improved after initiation of anakinra 
treatment. Axial CT on day 0 (C), when anakinra treatment was started, shows 
interlobular and intralobular septal thickening and rounded ground-glass 
opacities, predominantly in a peripheral distribution in both lungs; small 
peripheral or subpleural areas of subsegmental collapse or consolidation are 
noted, particularly at the bases. Axial CT on day 11 (D) shows a severely dilated 
left mainstem coronary artery (arrow) and proximal left anterior descending 
artery (Z-score 6·6 on echocardiography [not shown] and CT). Laboratory and 
clinical (core temperature) variables (E) indicate rapid and sustained 
improvement temporally associated with anakinra treatment (started day 0). 
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that contributes to cyto kine storm syndrome and organ 
damage, includ ing ARDS.6 In addition to the direct 
cytopathic effect inflicted on target organs, pulmonary 
damage seen in COVID-19 is probably augmented, if 
not dominated, by an unopposed dysregulated immune 
response. ARDS can occur in patients with primary or 
secondary cytokine storm syndrome, including systemic 
juvenile idiopathic arthritis, resembling the clinical 
picture in the reported patient. This finding could account 
for the rapid onset of clinical and imaging findings.7 
Since the patient showed altered clotting (prolonged 
prothrombin time and activated partial thromboplastin 
time, and increased D-dimer) in the presence of 
antiphospholipid antibodies and pathologically reduced 
serum complement levels, immune complex genera-
tion and deposition could, in addition to endothelial 
activation through IL-1, have contributed to activation 
of the complement and clotting cascades.8 Indeed, post-
infectious antiphospholipid syn drome with thrombo-
embolism has been reported in the context of COVID-19.9 
Furthermore, complement activa tion can take place 
in systemic inflammatory disorders, such as systemic 
juvenile idiopathic arthritis-associated macrophage acti-
va tion syndrome.10
Off-label treatment with anakinra was chosen to limit 
proinflammatory cytokine expression, which could have 
been triggered by antibody-dependent enhancement 
or invasion of yet uninfected immune cells to infected 
tissues. Of note, anakinra blocks IL-1 receptor signalling, 
which induces the expression of IL-1, IL-6, and TNF via 
activation of NF-κB-dependent pathways.11 Although 
most clinical trials currently underway investigate 
IL-6 blockade, we chose anakinra based on its action 
upstream of IL-6 and because of less neutropenia, liver 
enzyme elevation, and hypertriglyceridemia, which are 
already present in patients with cytokine storm syn-
drome. Furthermore, anakinra reduces mortality in 
sepsis patients,12 whereas chronic use of IL-6 blocking 
agents might increase the risk of secondary infections. 
Anakinra treatment coincided with clinical improvement 
and was stopped after 6 days.
During the ongoing pandemic, COVID-19 must be 
considered in patients with increased inflammatory 
vari ables and abdominal symptoms. The onset of cyto-
kine storm syndrome and ARDS can be rapid and life-
threatening. Based on the time of testing, the site of 
infection, or both, PCR testing might remain negative. 
Anakinra is safe and effective in other inflammatory and 
auto inflammatory disorders, and it could be beneficial in 
COVID-19-associated cytokine storm syndrome, in which 
disordered host responses contribute to path ology. 
Inflammatory endothelial activation, antiphospho lipid 
antibodies, and complement activation all promote a 
pro inflammatory and coagulopathic state. Anti throm-
botic prophylaxis should be considered, particularly in 
the presence of coronary artery dilation or aneurysm. 
Pros pective controlled trials are necessary to generate 
evidence for stage-specific and individualised treatment 
options in COVID-19.
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